Influence of HLA-DR Phenotype on the Risk of Hepatitis C Virus-Associated Mixed Cryoglobulinemia

Arthritis and Rheumatism

Volumn 44, Issue 9, 2001, Pages 2118-2124

  Cacoub, Patrice ^a   Renou, Christophe ^b   Kerr, Gail ^c   Hüe, Sophie ^d   Rosenthal, Eric ^e   Cohen, Pascal ^f   Kaplanski, Gilles ^g   Charlotte, Frédéric ^a   Thibault, Vincent ^a   Ghillani, Pascale ^a   Piette, Jean Charles ^a   Caillat Zucman, Sophie ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre Hospitalier Général de Hyères   (France)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f AVICENNE HOSPITAL   (France)

^g HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQ ANTIGEN; HLA DR ANTIGEN;

ADULT; AGED; ARTICLE; CRYOGLOBULINEMIA; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTOR; STATISTICAL MODEL; VIROLOGY;

ADULT; AGED; CRYOGLOBULINEMIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS;

EID: 18044402767     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200109)44:9<2118::AID-ART364>3.0.CO;2-X     Document Type: Article

References (58)

1. Casato M, Pucillo LP, Lagana B, Taliani G, Goffredo F, Bonomo L. Cryoglobulinaemia and hepatitis C virus. Lancet 1991;337: 1047-50.
2. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991;34:1606-10.
3. Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992;117:573-7.
4. Dammaco F, Sansonno D. Antibodies to hepatitis C virus in essential mixed cryoglobulinemia. Clin Exp Immunol 1992;87: 352-6.
5. Cacoub P, Musset L, Lunel-Fabiani F, Léger JM, Thi Huong Du L, Wechsler B, et al. Hepatitis C virus and essential mixed cryoglobulinemia. Br J Rhcumatol 1993;32:685-92.
6. Cacoub P, Lunel-Fabiani F, Musset L, Opolon P, Piette JC. Hepatitis C virus and cryoglobulinemia. N Engl J Med 1993;328: 1121-2.
7. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327: 1490-5.
8. Cacoub P, Lunel-Fabiani F, Musset L, Perrin M, Frangeul L, Léger JM, et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med 1994;96:124-32.
9. Meltzer M, Elias K, McCluskey RT, Cooper N, Franklin EC. Cryoglobulinemia: a clinical and laboratory study. Am J Med 1966;40:837-56.
10. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308.
11. Lunel-Fabiani F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994;106: 1291-1300.
12. Frangeul L, Musset L, Cresta P, Cacoub P, Huraux JM, Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996;25:427-32.
13. Willems M, Sheng L, Roskams T, Ramdani B, Doutrelepont JM, Nevens F, et al. Hepatitis C virus and its genotypes in patients suffering from chronic hepatitis C with or without a cryoglobulinemia-related syndrome. J Med Virol 1994;44:266-71.
14. Zignego AL, Ferri C, Giannini C, Monti M, la Civita L, Careccia G, et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996;124:31-4.
15. Mussel L, Lunel F, Cacoub P, Mannant PR, Silvain C, Lacombe C, et al. Increased serum immunoglobulin G1 levels in hepatitis C virus infection. Hepatology 1995;21:1755-7.
16. Cacoub P, Musset L, Hausfater P, Ghillani P, Fabiani F, Charlotte F. et al. No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus infection (HCV) with or without cryoglobulinemia. Clin Exp Immunol 1998;113: 48-54.
17. Gianini C, Thiers V, Nousbaum JB, Stuyver L, Maertens G, Brechot C. Comparative analysis of two assays for genotyping hepatitis C virus (HCV) based on genotype-specific primers or probes. J Hepatol 1995;23:246-53.
18. Musset L, Diemert MC, Taibi F, Thi Huong Du L, Cacoub P, Léger JM, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992;38:798-802.
19. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. Am J Med 1974;57: 775-88.
20. The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
21. Knodcll RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of numerical scoring systems for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;5:431-5.
22. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben Yahia MB, Andre C, et al. Extrahepatic immunologie manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995;122:169-73.
23. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al, for the MULTIVIRC Group. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999;42:2204-12.
24. Cacoub P, Musset L, Amoura Z, Ghillani P, Chabre H, Lunel F, et al. Anti-cardiolipin, anti-β2 glycoprotein 1, and antinucleosome antibodies in hepatitis C virus infection with or without mixed cryoglobulinemia. J Rheumatol 1997;24:2139-44.
25. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients. Medicine (Baltimore) 1999;79:47-56.
26. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-21.
27. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1992;352:595-600.
28. Gozlan M. Update on HIV transmission and pathogenesis [letter]. Lancet 1995;346:1290.
29. Westby M, Manca F, Dalgleish AG. The role of host immune responses in determining the outcome of HIV infection. Immunol Today 1996;17:120-6.
30. Dc Vries RR, Mehra NK, Vaidya MC, Gupte MD, Meera Khan P, van Rood JJ. HLA-linked control of susceptibility to tuberculoid leprosy and association with HLA-DR types. Tissue Antigens 1980;16:294-304.
31. Van Eden W, Gonzalez NM, de Vries RR, Convit J, van Rood JJ. HLA-linked control of predisposition to lepromatous leprosy. J Infect Dis 1985;151:9-14.
32. Lara ML, Layrisse Z, Scorza JV, Garcia E, Stoikow Z, Granados J, et al. Immunogenetics of human American cutaneous leishmaniasis: study of HLA haplotypes in 24 families from Venezuela. Hum Immunol 1991;30:129-35.
33. Petzl-Erler ML, Belich MP, Queiroz-Telles F. Association of mucosal leishmaniasis with HLA. Hum Immunol 1991;32:254-60.
34. Meyer CG, Gallin M, Erttmann K, Brattig N, Schnittger L, Gelhaus A, et al. HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection. Proc Natl Acad Sci U S A 1994;91:7515-9.
35. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994;6:157-62.
36. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJ. Simmonds P, et al. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988;1:1185-8.
37. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibiliy complex genes on the course of HIV-1 infection. Nat Med 1996;2:405-11.
38. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S. Andrieu JM, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999;162:6942-6.
39. Descamps B, Jungers P, Naret C, Degott C, Zingraff J, Bach JF. HLA-A1, B8 phenotype association and HBs antigenemia evolution in 440 hemodialyzed patients. Digestion 1977;15:271-7.
40. Forzani B, Actis GC, Verme G, Amoroso A, Borelli I, Curtoni ES, et al. HLA-DR antigens in HBsAg-positive chronic active liver disease with and without association with delta infection. Hepatology 1984;4:1107-10.
41. Yang PM, Sung JL, Chen DS. HLA-A,B,C, and DR antigens in chronic hepatitis B viral infection. Hepatogastroenterology 1989; 36:363-6.
42. Almarri A, Batchelor JR. HLA and hepatitis B infection. Lancet 1994;344:1194-5.
43. Thursz MR, Kwiatkowski D, Allsopp C, Greenwood BM, Thomas HC, Hill A. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332:1065-9.
44. Congia M, Clemente MG, Dessi C, Cucca F, Mazzoleni AP, Frau F, et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996;24: 1338-41.
45. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997;113:1675-81.
46. Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, et al. Association between HLA class II alleles and protection or susceptibility to chronic hepatitis C. J Hepatol 1998;28:1-7.
47. Minton EJ, Smilie D, Neal KR, Irving WL, Underwood JC, James V. Association between MHC class II alleles and clearance of circulating hepatitis C virus. J Infect Dis 1998;178:39-44.
48. Amoroso A, Berrino M, Canale L, Cornaglia M, Guarrera S, Mazzola G, et al. Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type Il after hepatitis C virus infection? J Hepatol 1998;29:36-44.
49. Lenzi M, Frisoni M, Mantovani V, Ricci P, Muratori L, Francesconi R, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998;91:2062-6.
50. Mangia A, Gentile R, Cascavilla I, Margaglione M, Villani MR, Stella F, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999;30:984-9.
51. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC, for the HENCORE group. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999;354: 2119-24.
52. Asti M, Martinetti M, Zavaglia C, Cuccia MC, Gusberti L, Tinelli C, et al. HLA class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology 1999;29:1272-9.
53. Peano G, Menardi G, Ponzetto A, Fenoglio LM. HLA-DR5 antigen: a genetic factor influencing the outcome of hepatitis C virus infection? Arch Intern Med 1994;154:2733-6.
54. Renou C, Hue S, Cacoub P, Halfon P, Thibault V, Charlotte F, et al. Different HLA class II alleles prevent or favor the development of cirrhosis in HCV chronically infected patients [abstract]. Hepatology 2000;32:266A.
55. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-7.
56. Cramp ME, Carucci P. Rossol S, Chokshi S, Maertens G, Williams R, et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 1999;44:424-9.
57. Caillat-Zucman S, Garchon HJ, Timsit J, Assan R, Boitard C, Djilali-Saiah I, et al. HLA genetic heterogeneity of insulin dependent diabetes mellitus: indication for an age dependent susceptibility gradient. J Clin Invest 1992;90:2242-50.
58. Mattey DL, Hassell AB, Dawes PT, Ollier WER, Hajeer A. Interaction between tumor necrosis factor microsatellite polymorphisms and the HLA-DRB1 shared epitope in rheumatoid arthritis: influence on disease outcome. Arthritis Rheum 1999;42: 2698-704.